Publicaciones en las que colabora con Ascensión López Díaz de Cerio (22)

2024

  1. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

2023

  1. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  2. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

  2. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  3. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

  4. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

  5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2019

  1. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    Antiviral Therapy, Vol. 24, Núm. 4, pp. 313-319

2017

  1. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

    Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196

2009

  1. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes

    Scandinavian Journal of Immunology, Vol. 69, Núm. 2, pp. 80-89

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  3. Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses

    International Immunology, Vol. 15, Núm. 6, pp. 691-699

2002

  1. Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and E1 proteins

    Journal of Virology, Vol. 76, Núm. 10, pp. 5062-5070

2001

  1. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes

    Journal of Hepatology, Vol. 34, Núm. 2, pp. 321-329

  2. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

    European Journal of Immunology, Vol. 31, Núm. 6, pp. 1780-1789

  3. Inducción de distintos perfiles de citoquinas mediante péptidos reconocidos por linfocitos cd4+. Aplicación a la potenciación de respuestas citotóxicas y humorales

    Inducción de distintos perfiles de citoquinas mediante péptidos reconocidos por linfocitos cd4+. Aplicación a la potenciación de respuestas citotóxicas y humorales